- Home
- ELMD vs GNLX Comparison
ELMD vs GNLX Comparison
Compare ELMD & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELMD | GNLX |
|---|---|---|
| Founded | 1992 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 326.9M | 110.4M |
| IPO Year | 2010 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ELMD | GNLX |
|---|---|---|
| Price | $27.67 | $2.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $36.00 | $17.25 |
| AVG Volume (30 Days) | 90.8K | ★ 228.3K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 52.94 | 9.47 |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $54,716,000.00 | $8,000.00 |
| Revenue This Year | $15.59 | N/A |
| Revenue Next Year | $11.51 | N/A |
| P/E Ratio | $21.67 | ★ N/A |
| Revenue Growth | ★ 13.83 | N/A |
| 52 Week Low | $23.01 | $2.29 |
| 52 Week High | $47.40 | $8.54 |
Technical Indicators
Market Signals| Indicator | ELMD | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 35.70 | 42.41 |
| Support Level | $27.14 | $2.34 |
| Resistance Level | $28.35 | $2.86 |
| Average True Range (ATR) | 0.86 | 0.14 |
| MACD | 0.64 | 0.00 |
| Stochastic Oscillator | 77.56 | 28.57 |
Price Performance
Historical ComparisonAbout ELMD Electromed Inc.
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.